VKH
ZVRA icon

Virtu KCG Holdings’s Zevra Therapeutics ZVRA Stock Holding History

Virtu KCG Holdings’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-688
Closed -$49K – 3855
2016
Q3 		$49K Sell
688
-278
-29% -$19.8K ﹤0.01% 2787
2016
Q2 		$61K Buy
+966
New +$159K ﹤0.01% 2636
2015
Q3 		– Sell
-1,099
Closed -$323K – 3887
2015
Q2 		$323K Buy
+1,099
New +$240K 0.01% 1972

Other funds holding ZVRA

DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
AWA
Arete Wealth Advisors Chicago, Illinois $1.51B AUM 33.02% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return
PL
Parkwood LLC Cleveland, Ohio $1.4B AUM 33.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Virtu KCG Holdings's ZVRA Position: Q4 2016 in Review

Virtu KCG Holdings sold out of Zevra Therapeutics (ZVRA) in Q4 2016, closing a stake of 688 shares — an estimated $49K sold.

Virtu KCG Holdings first reported a position in ZVRA in Q2 2015 and held it in 3 quarters. The position peaked at $323K in Q2 2015. 36 funds tracked by Wall St. Rank hold ZVRA as of Q4 2016.

  • Virtu KCG Holdings reported no remaining Zevra Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Virtu KCG Holdings sold 688 Zevra Therapeutics shares in Q4 2016, an estimated $49K.
  • Virtu KCG Holdings first reported a position in Zevra Therapeutics in Q2 2015 and held it in 3 quarters.
  • Virtu KCG Holdings's Zevra Therapeutics position peaked at $323K in Q2 2015.
  • 36 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q4 2016.

Based on Virtu KCG Holdings's 13F filing for Q4 2016, filed 10 Feb 2017.